FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia

Article Link: FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia

21 November 2019 — AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1 The…

Source: FDA New Drug Approvals